Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial

Omid Sedighi, Atieh Makhlough, Ghasem Janbabai, Mohammad Neemi, Omid Sedighi, Atieh Makhlough, Ghasem Janbabai, Mohammad Neemi

Abstract

Background: Functional iron deficiency (FID) may cause erythropoietin resistance in patients under hemodialysis (HD). Since the role of chronic inflammation or oxidative stress in its pathogenesis is unclear, controversy remains to whether intravenous iron or intravenous ascorbic acid (an antioxidant) can improve this anemia due to decreased iron availability.

Objectives: The current study compared the effect of intravenous iron versus intravenous ascorbic acid in the management of FID in HD patients.

Patients and methods: Forty HD patients with hemoglobin (Hb) ≤ 11 g/dL, serum ferritin ≥ 500 ng/mL and transferrin saturation (TSAT) ≤ 25% were randomly divided into two groups. 20 patients received 100 mg of intravenous (IV) iron (group I), and 20 patients received 300 mg of IV ascorbic acid (group II) postdialysis, twice a week for 5 consecutive weeks. Hb and iron metabolism indices were measured before the onset of the study and after 12 weeks following therapy.

Results: Twenty one percent of all HD patients, exhibited high serum ferritin, low TSAT and sufficient data for analysis. Both Group I (n = 20) and Group II (n = 20) patients showed a significant increase in Hb, serum iron, and TSAT (P < 0.001). There were no significant differences between both groups in increasing Hb (P = 0.076), serum iron (P = 0.589), serum ferritin (0.725), and TSAT (P = 0.887).

Conclusions: This study showed that both IV iron and IV ascorbic acid can improve FID in HD patients. A larger randomized trial is warranted to determine the optimal management of FID in HD patients.

Keywords: Anemia, Iron-Deficiency; Ascorbic Acid; Renal Dialysis.

References

    1. Amgen CA. Thousand oaks. CA: Amgen; 2007. Amgen Inc: Aranesp prescribing information.
    1. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145. doi: 10.1053/j.ajkd.2006.03.010.
    1. Coyne D. Iron indices: what do they really mean? Kidney Int Suppl. 2006;(101):S4–8.
    1. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial. 2004;17(5):336–41. doi: 10.1111/j.0894-0959.2004.17359.x.
    1. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141–9.
    1. Keyhanian S, Taziki O. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl. 2008;19(6):933–6.
    1. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47(4):644–54. doi: 10.1053/j.ajkd.2005.12.025.
    1. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66(2):753–60. doi: 10.1111/j.1523-1755.2004.00797.x.
    1. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16(11):3403–10. doi: 10.1681/ASN.2005030226.
    1. Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis. 2006;48:S1–S105.
    1. Kopelman RC, Smith L, Peoples L, Biesecker R, Rizkala AR. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int. 2007;11(2):238–46. doi: 10.1111/j.1542-4758.2007.00175.x.
    1. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18(3):975–84. doi: 10.1681/ASN.2006091034.
    1. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372–9. doi: 10.1681/ASN.2007050606.
    1. Singh AK, Coyne DW, Shapiro W, Rizkala AR. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007;71(11):1163–71. doi: 10.1038/sj.ki.5002223.
    1. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 1998;13(11):2867–72.
    1. Taji Y, Morimoto T, Okada K, Fukuhara S, Fukui T, Kuwahara T. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients. J Nephrol. 2004;17(4):537–43.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner